Myelodysplastic Syndrome - Treatment Options, Symptoms, Causes & Diagnosis from MedifocusHealth

Myelodysplastic Syndromes > What Your Doctor is Reading About Myelodysplastic Syndromes > General Interest Articles

General Interest Articles

1. American Society of Hematology--48th Annual Meeting and Exposition. Therapeutic approaches for hematological cancers. 9-12 December 2006 Orlando, FL, USA.

Author: Tear S;
Institution: Thomson Scientific, Middlesex House, 34-42 Cleveland Street, London, W1T 4JE UK. steven.tear@thomson.com
Journal: IDrugs. 2007 Feb;10(2):84-6.

2. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma.

Author: Roboz GJ; Bennett JM; Coleman M; Ritchie EK; Furman RR; Rossi A; Jhaveri K; Feldman EJ; Leonard JP; Roboz GJ; Bennett JM; Coleman M; Ritchie EK; Furman RR; Rossi A; Jhaveri K; Feldman EJ; Leonard JP;
Institution: Division of Hematology/Oncology, Leukemia Program, Center for Lymphoma and Myeloma, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY 10021, USA. gar2001@med.cornell.edu
Journal: Leuk Res. 2007 Aug;31(8):1141-4. Epub 2007 May 1.
Abstract URL: Click here to view abstract

3. Rheumatoid arthritis patients with therapy-induced myelodysplastic syndrome present with long-term remission after recovery.

Author: Thonhofer R; Kriessmayr M; Thonhofer U; Wipfler E; Uitz E; Bahadori B; Eder S;
Institution: Department of Internal Medicine, State Hospital Muerzzuschlag.
Journal: Scand J Rheumatol. 2007 Mar-Apr;36(2):149-51.

4. Acute myeloid leukemia and myelodysplastic syndromes in older patients.

Author: Estey E;
Institution: Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. ehestey@mdanderson.org
Journal: J Clin Oncol. 2007 May 10;25(14):1908-15.
Abstract URL: Click here to view abstract

5. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia.

Author: Bacher U; Haferlach T; Kern W; Haferlach C; Schnittger S;
Institution: Bone Marrow Transplant Unit, University Hospital of Hamburg-Eppendorf, Hamburg, Germany.
Journal: Haematologica. 2007 Jun;92(6):744-52.
Abstract URL: Click here to view abstract

6. Favourable response to splenectomy in familial myelodysplastic syndrome.

Author: Abdul-Wahab J; Naznin M; Suhaimi A; Amir-Hamzah AR;
Institution: Department of Paediatrics, Faculty of Medicine, International Islamic University of Malaysia, PO Box 141, Kuantan 27510, Malaysia. nasyrah_wahab@yahoo.com
Journal: Singapore Med J. 2007 Jul;48(7):e206-8.
Abstract URL: Click here to view abstract

7. Treatment of bone marrow failure syndrome with integrated traditional and Western medicine.

Author: Ma R;
Institution: Hematology Disease Center, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China. xyxysys@yahoo.com.cn
Journal: Chin J Integr Med. 2007 Jun;13(2):85-8.

8. World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes.

Author: Bernasconi P; Klersy C; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Caresana M; Dambruoso I; Lazzarino M; Bernasconi C;
Institution: Division of Haematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy. p.bernasconi@smatteo.pv.it
Journal: Br J Haematol. 2007 May;137(3):193-205.
Abstract URL: Click here to view abstract

9. American Society of Hematology--48th Annual Meeting and Exposition. Updates on therapies. 9-12 December 2006 Orlando, FL, USA.

Author: Clemetson KJ;
Institution: University of Berne, Theodor Kocher Institute, Freiestrasse 1, CH-3012 Berne, Switzerland. clemetson@tki.unibe.ch
Journal: IDrugs. 2007 Feb;10(2):90-2.

10. The myelodysplastic syndromes.

Author: Sekeres MA;
Institution: Cleveland Clinic Lerner College of Medicine, Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio 44195, USA. sekerem@ccf.org
Journal: Expert Opin Biol Ther. 2007 Mar;7(3):369-77.
Abstract URL: Click here to view abstract

11. Myelodysplastic syndromes: incidence and survival in the United States.

Author: Ma X; Does M; Raza A; Mayne ST;
Institution: Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, Connecticut 06520, USA. xiaomei.ma@yale.edu
Journal: Cancer. 2007 Apr 15;109(8):1536-42.
Abstract URL: Click here to view abstract

12. The incidence and impact of thrombocytopenia in myelodysplastic syndromes.

Author: Kantarjian H; Giles F; List A; Lyons R; Sekeres MA; Pierce S; Deuson R; Leveque J;
Institution: Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, Texas.
Journal: Cancer. 2007 Mar 15;109(9):1705-1714.
Abstract URL: Click here to view abstract

13. Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes.

Author: Golshayan AR; Jin T; Maciejewski J; Fu AZ; Bershadsky B; Kattan MW; Kalaycio ME; Sekeres MA;
Institution: Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH 44195, USA.
Journal: Br J Haematol. 2007 Apr;137(2):125-32.
Abstract URL: Click here to view abstract

14. The clinical, haematological and morphological profile of patients with myelodysplastic syndromes: a single institution experience from Turkey.

Author: Demirkan F; Alacacioglu I; Piskin O; Ozsan HG; Akinci B; Ozcan AM; Yavuzsen T; Yuksel E; Undar B;
Institution: Division of Hematology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey. fatih.demirkan@deu.edu.tr
Journal: Leuk Lymphoma. 2007 Jul;48(7):1372-8.
Abstract URL: Click here to view abstract

15. Early acute myeloblastic leukemia treatment for childhood myelodysplastic syndrome with t(3;5) (NPM/MLF1).

Author: Sevilla J; Fernandez-Plaza S; Lassaletta A; Gonzalez-Vicent M; Contra T; Madero L;
Institution: Oncohematologia pediatrica Hospital Nino Jesus, Madrid, Spain. jsevilla.hnjs@salud.madrid.org
Journal: J Pediatr Hematol Oncol. 2007 Dec;29(12):839-40.
Abstract URL: Click here to view abstract

16. Iron overload in myelodysplastic syndromes (MDS) - diagnosis, management, and response criteria: a proposal of the Austrian MDS platform.

Author: Valent P; Krieger O; Stauder R; Wimazal F; Nosslinger T; Sperr WR; Sill H; Bettelheim P; Pfeilstocker M;
Institution: Department of Internal Medicine I, Division of Haematology & Haemostaseology, Medical University of Vienna, Austria. peter.valent@meduniwien.ac.at
Journal: Eur J Clin Invest. 2008 Mar;38(3):143-9. Epub 2008 Jan 24.
Abstract URL: Click here to view abstract

17. Meeting report: myelodysplastic syndromes at ASH 2007.

Author: Itzykson R; Gardin C; Fenaux P;
Institution: Service d'hematologie clinique, Hopital Avicenne, Bobigny, France.
Journal: Leukemia. 2008 May;22(5):893-7. Epub 2008 Mar 6.
Abstract URL: Click here to view abstract

18. Advances in the treatment of myelodysplastic syndromes.

Author
Institution
Journal: Clin Adv Hematol Oncol. 2008 Mar;6(3 Suppl 6):1-13; discussion 14; quiz 15-6.
Abstract URL: Click here to view abstract

19. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy.

Author: Sloand EM; Wu CO; Greenberg P; Young N; Barrett J;
Institution: National Heart, Lung and Blood Institute, Division of Intramural Research, Hematology Branch, Bethesda, MD 20892, USA. sloande@nhlbi.nih.gov
Journal: J Clin Oncol. 2008 May 20;26(15):2505-11. Epub 2008 Apr 14.
Abstract URL: Click here to view abstract

20. A prognostic score for patients with lower risk myelodysplastic syndrome.

Author: Garcia-Manero G; Shan J; Faderl S; Cortes J; Ravandi F; Borthakur G; Wierda WG; Pierce S; Estey E; Liu J; Huang X; Kantarjian H;
Institution: Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. ggarciam@mdanderson.org
Journal: Leukemia. 2008 Mar;22(3):538-43. Epub 2007 Dec 13.
Abstract URL: Click here to view abstract

21. Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey.

Author: Steensma DP; Heptinstall KV; Johnson VM; Novotny PJ; Sloan JA; Camoriano JK; Niblack J; Bennett JM; Mesa RA;
Institution: Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, United States. steensma.david@mayo.edu
Journal: Leuk Res. 2008 May;32(5):691-8. Epub 2007 Dec 4.
Abstract URL: Click here to view abstract

22. Chromosome 5q deletion: specific diagnoses and cytogenetic details among 358 consecutive cases from a single institution.

Author: Santana-Davila R; Holtan SG; Dewald GW; Ketterling RP; Knudson RA; Hanson CA; Steensma DP; Tefferi A;
Institution: Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.
Journal: Leuk Res. 2008 Mar;32(3):407-11. Epub 2007 Aug 20.
Abstract URL: Click here to view abstract

23. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy.

Author: Czuczman MS; Emmanouilides C; Darif M; Witzig TE; Gordon LI; Revell S; Vo K; Molina A;
Institution: Roswell Park Cancer Institute, Buffalo, NY 14263, USA. myron.czuczman@roswellpark.org
Journal: J Clin Oncol. 2007 Sep 20;25(27):4285-92. Epub 2007 Aug 20.
Abstract URL: Click here to view abstract

24. Rare t(1;11)(q23;p15) in therapy-related myelodysplastic syndrome evolving into acute myelomonocytic leukemia: a case report and review of the literature.

Author: Zhang L; Alsabeh R; Mecucci C; La Starza R; Gorello P; Lee S; Lill M; Schreck R;
Institution: Department of Pathology and Laboratory, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Room 4711, Los Angeles, CA 90048, USA. zhang11999@yahoo.com
Journal: Cancer Genet Cytogenet. 2007 Oct 1;178(1):42-8.
Abstract URL: Click here to view abstract

25. Skin cancer after nonmyeloablative hematopoietic cell transplantation.

Author: Cavalier M; Shmalo JA; Yu M; Billings SD; Abonour R; Nelson RP Jr;
Institution: Department of Pediatric Hematology/Oncology, Indiana University School of Medicine, 535 Barnhill Drive, Indianapolis, IN 46202, USA.
Journal: Bone Marrow Transplant. 2006 Jun;37(12):1103-8.
Abstract URL: Click here to view abstract

26. Myelodysplastic syndromes clinical practice guidelines in oncology.

Author: Greenberg PL; Baer MR; Bennett JM; Bloomfield CD; De Castro CM; Deeg HJ; Devetten MP; Emanuel PD; Erba HP; Estey E; Foran J; Gore SD; Millenson M; Navarro WH; Nimer SD; O'Donnell MR; Saba HI; Spiers K; Stone RM; Tallman MS; Greenberg PL; Baer MR; Bennett JM; Bloomfield CD; De Castro CM; Deeg HJ; Devetten MP; Emanuel PD; Erba HP; Estey E; Foran J; Gore SD; Millenson M; Navarro WH; Nimer SD; O'Donnell MR; Saba HI; Spiers K; Stone RM; Tallman MS;
Institution: Stanford Hospital and Clinics, Stanford, CA, USA.
Journal: J Natl Compr Canc Netw. 2006 Jan;4(1):58-77.

27. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.

Author: Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR; Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR;
Institution: Department of Medicine and Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA. dlh23@columbia.edu
Journal: J Natl Cancer Inst. 2007 Feb 7;99(3):196-205.
Abstract URL: Click here to view abstract

28. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference.

Author: Valent P; Horny HP; Bennett JM; Fonatsch C; Germing U; Greenberg P; Haferlach T; Haase D; Kolb HJ; Krieger O; Loken M; van de Loosdrecht A; Ogata K; Orfao A; Pfeilstocker M; Ruter B; Sperr WR; Stauder R; Wells DA; Valent P; Horny HP; Bennett JM; Fonatsch C; Germing U; Greenberg P; Haferlach T; Haase D; Kolb HJ; Krieger O; Loken M; van de Loosdrecht A; Ogata K; Orfao A; Pfeilstocker M; Ruter B; Sperr WR; Stauder R; Wells DA;
Institution: Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria. peter.valent@meduniwien.ac.at
Journal: Leuk Res. 2007 Jun;31(6):727-36. Epub 2007 Jan 25.
Abstract URL: Click here to view abstract

29. A Decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes.

Author: Sekeres MA; Fu AZ; Maciejewski JP; Golshayan AR; Kalaycio ME; Kattan MW;
Institution: Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio 44195, USA. sekerem@ccf.org
Journal: Cancer. 2007 Mar 15;109(6):1125-32.
Abstract URL: Click here to view abstract

30. Myelodysplastic and myeloproliferative disorders in children.

Author: Hasle H;
Institution: Department of Pediatrics, Aarhus University Hospital Skejby, Aarhus, Denmark. Hasle@dadlnet.dk
Journal: Curr Opin Pediatr. 2007 Feb;19(1):1-8.
Abstract URL: Click here to view abstract

31. Myelodysplastic syndromes in patients younger than age 50.

Author: Kuendgen A; Strupp C; Aivado M; Hildebrandt B; Haas R; Gattermann N; Germing U;
Institution: Department of Hematology, Oncology, and Clinical Immunology, and Institute of Human Genetics, Heinrich-Heine-University, Duesseldorf, Germany. kuendgen@med.uni-duesseldorf.de
Journal: J Clin Oncol. 2006 Dec 1;24(34):5358-65. Epub 2006 Nov 6.
Abstract URL: Click here to view abstract

32. Survivin expression in "low-risk" and "high-risk" myelodysplastic syndromes.

Author: Gianelli U; Fracchiolla NS; Cortelezzi A; Pellegrini C; Savi F; Moro A; Grimoldi MG; Deliliers GL; Coggi G; Bosari S;
Institution: II Cattedra di Anatomia Patologica, Dipartimento di Medicina, Chirurgia e Odontoiatria, Universita degli Studi di Milano, A. O. S. Paolo e Fondazione Ospedale Maggiore Policlinico, Via Di Rudini', 8, Mangiagalli e Regina Elena di Milano, 20142, Italy, umberto.gianelli@alice.it.
Journal: Ann Hematol. 2007 Mar;86(3):185-189. Epub 2006 Nov 24.
Abstract URL: Click here to view abstract

33. Managing Patients With Low-Risk MDS.

Author: Sekeres MW; Cosgrove D; Falco A;
Institution: Taussig Cancer Center, Cleveland Clinic, Cleveland, OH 44195, U.S.A.
Journal: Clin Adv Hematol Oncol. 2006 Jul;4 Suppl 16(7):1-12.
Abstract URL: Click here to view abstract

34. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome.

Author: Malcovati L; Della Porta MG; Cazzola M;
Institution
Journal: Haematologica. 2006 Dec;91(12):1588-90.

35. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.

Author: Le Deley MC; Suzan F; Cutuli B; Delaloge S; Shamsaldin A; Linassier C; Clisant S; de Vathaire F; Fenaux P; Hill C; Le Deley MC; Suzan F; Cutuli B; Delaloge S; Shamsaldin A; Linassier C; Clisant S; de Vathaire F; Fenaux P; Hill C;
Institution: Biostatistics and Epidemiology Unit, Department of Medicine, , Institut Gustave-Roussy, Villejuif, France. le_deley@igr.fr
Journal: J Clin Oncol. 2007 Jan 20;25(3):292-300. Epub 2006 Dec 11.
Abstract URL: Click here to view abstract